Cambridge-based Infinity Pharmaceuticals Inc. said that its 5.7 million-share offering priced flat with Wednesday’s close of $26.33, as it seeks to raise funds for research and development costs, potential acquisitions and other purposes, Dow Jones reported. Infinity’s shares had climbed to their highest level in a decade on Tuesday after the company reported positive results from an early clinical trial of its drug IPI-145 as a treatment for blood cancers.
Infinity completes 5.7m share offering
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week